Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Mereo BioPharma Group (MREO) Shares Outstanding (Weighted Average): 2020-2025

Historic Shares Outstanding (Weighted Average) for Mereo BioPharma Group (MREO) over the last 3 years, with Sep 2025 value amounting to $795.5 million.

  • Mereo BioPharma Group's Shares Outstanding (Weighted Average) rose 3.41% to $795.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $795.5 million, marking a year-over-year increase of 3.41%. This contributed to the annual value of $795.0 million for FY2024, which is 13.35% up from last year.
  • According to the latest figures from Q3 2025, Mereo BioPharma Group's Shares Outstanding (Weighted Average) is $795.5 million, which was down 0.00% from $795.5 million recorded in Q2 2025.
  • In the past 5 years, Mereo BioPharma Group's Shares Outstanding (Weighted Average) ranged from a high of $795.5 million in Q2 2025 and a low of $544.5 million during Q2 2021.
  • Over the past 3 years, Mereo BioPharma Group's median Shares Outstanding (Weighted Average) value was $769.3 million (recorded in 2024), while the average stood at $730.3 million.
  • Data for Mereo BioPharma Group's Shares Outstanding (Weighted Average) shows a peak YoY spiked of 455.85% (in 2021) over the last 5 years.
  • Mereo BioPharma Group's Shares Outstanding (Weighted Average) (Quarterly) stood at $584.9 million in 2021, then remained steady at $584.9 million in 2022, then rose by 19.91% to $701.4 million in 2023, then rose by 13.35% to $795.0 million in 2024, then grew by 3.41% to $795.5 million in 2025.
  • Its last three reported values are $795.5 million in Q3 2025, $795.5 million for Q2 2025, and $795.0 million during Q1 2025.